Fig. 1.

FDA-approved therapeutical options for MM and date of their first approval. PI—proteasome inhibitors, IMiDs—immunomodulatory drugs, HDACi—histone deacetylase inhibitors, mAbs—monoclonal antibodies, ADC—antibody–drug conjugates, SINEs—selective inhibitors of nuclear export, CAR—CAR T cell therapies, BiTE—bispecific T cell engagers